Inflammation as a Therapeutic Target for Diabetic Neuropathies.
about
Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptorMediators of diabetic neuropathy: is hyperglycemia the only culprit?Peripheral Neuropathy and Hindlimb Paralysis in a Mouse Model of Adipocyte-Specific Knockout of Lkb1.Temporal trend of autonomic nerve function and HSP27, MIF and PAI-1 in type 1 diabetesGMSC-Derived Exosomes Combined with a Chitosan/Silk Hydrogel Sponge Accelerates Wound Healing in a Diabetic Rat Skin Defect Model.Autologous Bone Marrow-Derived Stem Cells for Treating Diabetic Neuropathy in Metabolic Syndrome.Ptosis as the only manifestation of diabetic superior division oculomotor nerve palsy: A case report.Role of inflammatory biomarker in diabetic peripheral neuropathy.MicroRNA-146a Mimics Reduce the Peripheral Neuropathy in Type 2 Diabetic Mice.Structured lifestyle intervention in patients with the metabolic syndrome mitigates oxidative stress but fails to improve measures of cardiovascular autonomic neuropathy.Association between HbA1c and peripheral neuropathy in a 10-year follow-up study of people with normal glucose tolerance, impaired glucose tolerance and Type 2 diabetes.Involvement of microRNA-146a in diabetic peripheral neuropathy through the regulation of inflammation.Nanoparticle-Encapsulated Curcumin Inhibits Diabetic Neuropathic Pain Involving the P2Y12 Receptor in the Dorsal Root Ganglia.Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy.Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: An inflammatory story.The Diabetic Foot as a Proxy for Cardiovascular Events and Mortality Review.Differential mRNA expression of neuroinflammatory modulators in the spinal cord and thalamus of type 2 diabetic monkeys.Susceptibility of Diabetic Mice to Noise Trauma.
P2860
Q37239135-30EB0D8E-FEEA-4C12-80C2-005AA95E71CCQ39015184-05B99C0A-4967-41A9-AAC8-43C548CE49B7Q42651355-DD85046C-236C-46E8-B3EE-0D3979378402Q42656381-6E33BD0C-2ED7-45B5-AFDE-DD762D17E884Q46154087-00537A87-AFE2-4BBD-B17B-655A5C91F382Q47094987-EC73F05B-0BC2-4BE9-8163-44829865CD8CQ47161033-1C6FE52E-A578-49C4-8FB9-8C68AE72B527Q47217664-2809DC62-21B0-4A54-91CC-5887824EF54CQ47814946-474FE2E1-048C-4005-8D26-0DD909053E5CQ47832918-541AA8E5-2523-4674-B29B-F34DEB60BD30Q47956113-FE7F2425-0FF5-4C6B-BCA6-F843D88C9374Q49337399-8A519770-9887-4C07-B0D9-B4382D18CAE3Q49816634-680EDDC5-5524-4AE8-8F90-8CA559AB7EEAQ51733350-0630753B-F95A-4454-A0C1-AF085118957EQ52650664-9F862B43-10DB-4BF8-BEBF-CFDC61A6503EQ53723838-14D26438-8577-4C18-81F3-E637576B0023Q54089317-A5445E35-8939-4851-A965-01A3A0396CA5Q55325984-38800BF9-F8CF-45AE-9816-B2425590D888
P2860
Inflammation as a Therapeutic Target for Diabetic Neuropathies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inflammation as a Therapeutic Target for Diabetic Neuropathies.
@en
Inflammation as a Therapeutic Target for Diabetic Neuropathies.
@nl
type
label
Inflammation as a Therapeutic Target for Diabetic Neuropathies.
@en
Inflammation as a Therapeutic Target for Diabetic Neuropathies.
@nl
prefLabel
Inflammation as a Therapeutic Target for Diabetic Neuropathies.
@en
Inflammation as a Therapeutic Target for Diabetic Neuropathies.
@nl
P2093
P2860
P1476
Inflammation as a Therapeutic Target for Diabetic Neuropathies
@en
P2093
Crystal Holmes
Katherine Gallagher
P2860
P2888
P356
10.1007/S11892-016-0727-5
P577
2016-03-01T00:00:00Z